CJEU Urged To Take Harder Line On Servier Perindopril Agreements
Advocate General Suggests CJEU Should Set Aside Certain General Court Findings
European allegations of abuses of dominant positions in the pharmaceutical sector may once again be reframed, after the CJEU was advised by advocate general Juliane Kokott to set aside certain findings of the General Court on settlement deals made by Servier with multiple generics firms over perindopril.
You may also be interested in...
Krka has explained a near double-digit percentage point drop for its EBITDA margin, as it presented preliminary results for the first half of 2022.
The EU’s General Court judgement in the Servier pay-for-delay case will put more pressure on competition authorities to show evidence of alleged abuse of a dominant position.
With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.